Videos

Investing in innovators: Learn more about the Cancer Immunotherapy ETF’s components with our exclusive series of CEO interviews below.

Watch Videos

Cellectis

Gene editing is a paradigm shift in the field of cell therapy, immuno-oncology, and medicine in general and that’s where Cellectis is trying to make the point." − André Choulika Chairman & CEO, CEllectis

Adaptimmune

I don’t think anything could be more exciting than trying to have a major effect on cancer patients. It’s a privilege, to be honest, to be involved in such an exciting field." − James Noble CEO, Adaptimmune

Advaxis

Cancer is an individualized disease. Our technology lends itself towards treating a patient’s individualized antigens that are discreet and personal to that patient.”" − Dan O’Connor CEO, Advaxis

Opinions expressed are those of the author or Funds and are subject to change, are not intended to be a forecast of future events, a guarantee of future results, nor investment advice.